{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PINK1",
        "Protein_Change": {
          "ref": "G",
          "alt": "D",
          "position": 309
        },
        "variant_string_id": "PINK1 G309D"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the PTEN induced putative kinase 1 (PINK1) gene cause an autosomal recessive form of Parkinson disease (PD).",
          "judgment": "Yes",
          "reasoning": "Paper clearly defines that PINK1 mutations are involved in the pathogenesis of Parkinson disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "PINK1 phosphorylates TRAP1, and the kinase activity is abrogated by PD-linked mutations.",
          "judgment": "Yes",
          "reasoning": "Kinase assays are used to evaluate PINK1's ability to phosphorylate TRAP1, which is relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Wild-type and mutant PINK1 proteins were assayed for their ability to phosphorylate TRAP1 in vitro and in vivo. Controls included wild-type PINK1 and known pathogenic mutants.",
          "judgment": "Yes",
          "reasoning": "Assays included appropriate controls (wild-type and known pathogenic mutants) and were performed in multiple replicates."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The G309D mutation virtually abolished the kinase activity of PINK1 in vitro and in vivo.",
          "judgment": "Yes",
          "reasoning": "The G309D mutation significantly impaired PINK1's ability to phosphorylate TRAP1, indicating a loss of function."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The G309D mutation severely impairs PINK1's kinase activity, leading to a loss of function that correlates with pathogenicity in Parkinson disease."
    },
    {
      "variant_id": {
        "Gene": "PINK1",
        "Protein_Change": {
          "ref": "L",
          "alt": "P",
          "position": 347
        },
        "variant_string_id": "PINK1 L347P"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the PTEN induced putative kinase 1 (PINK1) gene cause an autosomal recessive form of Parkinson disease (PD).",
          "judgment": "Yes",
          "reasoning": "Paper clearly defines that PINK1 mutations are involved in the pathogenesis of Parkinson disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "PINK1 phosphorylates TRAP1, and the kinase activity is abrogated by PD-linked mutations.",
          "judgment": "Yes",
          "reasoning": "Kinase assays are used to evaluate PINK1's ability to phosphorylate TRAP1, which is relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Wild-type and mutant PINK1 proteins were assayed for their ability to phosphorylate TRAP1 in vitro and in vivo. Controls included wild-type PINK1 and known pathogenic mutants.",
          "judgment": "Yes",
          "reasoning": "Assays included appropriate controls (wild-type and known pathogenic mutants) and were performed in multiple replicates."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The L347P mutation virtually abolished the kinase activity of PINK1 in vitro and in vivo.",
          "judgment": "Yes",
          "reasoning": "The L347P mutation significantly impaired PINK1's ability to phosphorylate TRAP1, indicating a loss of function."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The L347P mutation severely impairs PINK1's kinase activity, leading to a loss of function that correlates with pathogenicity in Parkinson disease."
    },
    {
      "variant_id": {
        "Gene": "PINK1",
        "Protein_Change": {
          "ref": "W",
          "alt": "*",
          "position": 437
        },
        "variant_string_id": "PINK1 W437X"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the PTEN induced putative kinase 1 (PINK1) gene cause an autosomal recessive form of Parkinson disease (PD).",
          "judgment": "Yes",
          "reasoning": "Paper clearly defines that PINK1 mutations are involved in the pathogenesis of Parkinson disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "PINK1 phosphorylates TRAP1, and the kinase activity is abrogated by PD-linked mutations.",
          "judgment": "Yes",
          "reasoning": "Kinase assays are used to evaluate PINK1's ability to phosphorylate TRAP1, which is relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Wild-type and mutant PINK1 proteins were assayed for their ability to phosphorylate TRAP1 in vitro and in vivo. Controls included wild-type PINK1 and known pathogenic mutants.",
          "judgment": "Yes",
          "reasoning": "Assays included appropriate controls (wild-type and known pathogenic mutants) and were performed in multiple replicates."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "The W437X mutation had no significant effect on PINK1-mediated TRAP1 phosphorylation in vitro but caused a 30% to 45% reduction in both basal and oxidative-stress-induced levels of TRAP1 phosphorylation in vivo.",
          "judgment": "Yes",
          "reasoning": "The W437X mutation has a partial inhibitory effect on PINK1's kinase activity in vivo, suggesting a partial loss of function."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The W437X mutation partially impairs PINK1's kinase activity, leading to a partial loss of function that may contribute to pathogenicity in Parkinson disease."
    }
  ]
}